Avantor enters its July 29 earnings with a notable divergence: analysts are lifting price targets at a faster pace than at any point this year, yet short sellers have quietly rebuilt positions by more than 20% over the past month.
The most eye-catching development this week is the analyst re-rating. The Street has turned measurably less bearish on AVTR in recent weeks. Citigroup raised its target from $9 to $11 on July 8 while keeping a Neutral rating — a meaningful 22% lift. Evercore ISI moved its target from $8 to $10.50, and Bernstein reinstated with a Market Perform at $10.50 after stepping away. Even Barclays, which holds an Underweight, nudged its target up from $7 to $8. None of these moves signal conviction that the stock is a buy, but the direction of travel is clear: the bear case is softening. With AVTR trading at $10.20 and the consensus mean target at $10.06, the Street is clustered tightly around the current price — an unusual setup that signals genuine uncertainty rather than a defined directional call.
Options positioning supports the bullish lean, but with a historical asterisk. The put/call ratio has collapsed to 0.31, a 52-week low and well below the 20-day average of 2.23. That 20-day average is itself distorted by a prolonged period of heavy put accumulation that ran from late May through mid-June, when the ratio sat above 4 and at times above 7. That protective positioning has been completely unwound. The current reading is 0.88 standard deviations below the mean — technically within normal range given the wide dispersion — but the directionality is unambiguous: traders who spent months buying downside protection have shifted sharply toward calls ahead of the print.
Short interest tells a more complicated story. Bears have added meaningfully — short interest rose 21% over the past month to reach 6.7% of the free float, roughly 45.4 million shares. That is a real build, and it comes as the stock has recovered 11% over the past month to $10.20. The borrow market, however, shows no signs of stress. Availability is running at 726%, meaning there are more than seven shares available to lend for every one currently borrowed — well within the normal range and actually up from about 1,000% in early June before the short build began. Cost to borrow is 0.52%, a 30-day high but still firmly in "easy borrow" territory. Bears are building positions but facing no squeeze pressure.
The institutional register offers a supporting subplot. Dodge & Cox holds 17.5% of shares — the dominant position on the cap table — and added 2.6 million shares through Q1. Engine Capital, an activist-leaning manager, built a nearly 2.9% stake with an 8-million-share increase in the same period. BlackRock added 6.1 million shares through June. On the insider side, three directors made open-market purchases between February and May at prices ranging from $8.01 to $8.32 — all below current levels, and all with a trade significance score suggesting the buys were deliberate rather than routine. Net insider buying over 90 days totals roughly $315,000 across 38,000 shares. Small in dollar terms, but the direction is consistent.
What to watch into the July 29 print: whether the three most recent earnings reactions — one modest bounce, one sell-off — reflect a company that consistently disappoints on revenue guidance even when it beats on cost, and whether the bear_case narrative of persistent bioprocessing headwinds and further organic revenue contraction in Q3 has been sufficiently priced into a stock that has already retraced from $14 to $10 over the past year.
See the live data behind this article on ORTEX.
Open AVTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
